Objective To construct the machine learning models based on the radiomic features of non-contrast and enhanced CT and to evaluate the predictive value in the risk stratification of gastrointestinal stromal tumor(GIST).Methods A total of 182 patients with pathologically confirmed GIST were randomly divided into a training set and a validation set at a ratio of 7∶3.The volume of interest(VOI)was outlined in the non-contrast phase,arterial phase and venous phase,and its radiomic features were extracted.The most valuable radiomic features were selected using the least absolute shrinkage and selection operator(LASSO)algorithm.The logistic regression(LR)classifier was used to construct the prediction models based on single-phase or multi-phase images.The predictive efficacy of the different models was compared by using receiver operating characteristic(ROC)curves.Results Four,three,and four radiomic features were selected in the non-contrast phase,arterial phase and venous phase,and 4 models were constructed in total.Among the single-phase models,the venous phase had better predictive efficacy,with the area under the curve(AUC)of 0.932[95％confidence interval(CI)0.873-0.969]and 0.924(95％CI 0.819-0.979)in the training and validation sets.The predictive efficacy of the combined model was improved,with the AUC of 0.946(95％CI 0.891-0.978)and 0.938(95％CI 0.838-0.986).Conclusion The venous phase model can predict the risk stratification of GIST accurately,and the prediction efficacy can be improved by combining the non-contrast and arterial phases.

Objective:To explore the efficacy of adjusting the dose of imatinib dose in the context of therapeutic drug monitoring (TDM) in patients with gastrointestinal stromal tumors (GISTs) who are receiving adjuvant therapy after complete resection of their tumors.Methods:This was a descriptive study. Inclusion criteria were (1) complete surgical resection with a pathological diagnosis of GIST, (2) postoperative adjuvant therapy with imatinib and dosage adjustment, (3) multiple TDM of imatinib, and (4) complete clinical, pathological, and follow-up data. The data of 70 patients with GISTs treated at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology between January 2015 and December 2023 were collected retrospectively. The study cohort comprised 15 (21.4%) men and 55 (78.6%) women of median age 60 years (range: 25–82). Of the eligible patients, 49 (70.0%) were at high-risk, 14 (20.0%) at intermediate-risk, six (8.6%) at low-risk, and one (1.4%) at very low risk. Patients were followed up by the gastrointestinal stromal tumor clinic every 2–3 months and their plasma concentrations of imatinib were checked. The dose was adjusted to 300 mg/d or 200 mg/d depending on whether they had had ≥ grade III adverse reactions, and whether the first plasma concentration of imatinib was ≥ 1,500 μg/L or between the expected range of 760 μg/L–1,100 μg/L. Studied indicators included adverse reactions, quality of life before and after dose adjustment, and overall survival and recurrence-free survival (RFS) after dose adjustment.Results:Before dose adjustment, all 70 patients received 400 mg of imatinib daily, with initial TDM values of 1,900 ± 568 μg/L, for a median duration of 8.3 months. After dose adjustment, 60 patients received 300 mg daily, with a TDM of 1,216 ± 350 μg/L, whereas 10 received 200 mg daily, with a TDM of 1,023 ± 269 μg/L. The median duration of treatment after dose adjustment was 23.4 months. Compared with those whose dosages were not adjusted, the incidence of bone marrow suppression was significantly lower (74.3% [52/70] vs. 51.4% [36/70], χ 2=9.202, P=0.010); as were the incidences of edema (95.7% [67/70] vs. 50.0% [35/70], χ 2=40.526, P<0.001); skin reactions (70.0% [49/70] vs. 32.9% [23/70), χ 2=22.495, P<0.001); and gastrointestinal reactions (38.6% [27/70] vs. 10.0% [7/70], χ 2=15.899, P<0.001) in those whose dosages were adjusted. The average total scores for physical health before and after dose adjustment were 76 ± 5 and 88 ± 4, respectively; whereas the mental health scores were 75 ± 6 and 89 ± 4, respectively. The median follow-up period was 36 months (range 6–126). During the first 3 years of follow-up, five high-risk patients with non-gastric GISTs developed recurrences. The 3-year overall survival rate was 100%, and the 3-year RFS rate was 92.8%, high-risk patients having a 3-year RFS rate of 89.8%. Conclusion:The adverse reactions and quality of life of GIST patients with severe adverse reactions to adjuvant imatinib therapy after complete resection can be mitigated by appropriately reducing the dosage of imatinib under the guidance of TDM.

Objective:To analyze the clinical application value of serum heme oxygenase (HO)-1expression level in non-alcoholic fatty liver disease (NAFLD) and, based on that, establish a diagnostic model combined with glucose regulatory protein 78 (GRP78) so as to clarify its diagnostic effectiveness and application value.Methods:A total of 210 NAFLD patients diagnosed by abdominal B-ultrasound and liver elastography were included, and at the same time, 170 healthy controls were enrolled. The general clinical data, peripheral blood cell counts, and biochemical indicators of the research subjects were collected. The expression levels of HO-1 and GRP78 were detected using an enzyme-linked immunosorbent assay. Multivariate analysis was used to screen independent risk factors for NAFLD. Visual output was performed through nomogram diagrams, and the diagnostic model was constructed. Receiver operating characteristic curve (ROC), calibration curve, and decision curve analysis (DCA) were used to evaluate the diagnostic effectiveness of NAFLD. Measurement data were analyzed using a t-test or Mann-Whitney U rank sum test to detect data differences between groups. Enumeration data were analyzed using the Fisher's exact probability test or the Pearson χ2 test. Results:Compared with the healthy control group, the white blood cell count, aspartate aminotransferase (AST), alanine aminotransferase, gamma-glutamyl transferase (GTT), fasting blood glucose (Glu), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), serum HO-1, and GRP78 levels were significantly increased in the NAFLD group patients ( P ?

Objective:To investigate the predictive value of clinical factor model, deep learning model based on baseline plain CT images, and combination of both for predicting hematoma expansion in cerebral hemorrhage.Methods:The study was cross-sectional. Totally 471 cerebral hemorrhage patients who were firstly diagnosed in the Second Affiliated Hospital of Soochow University from January 2017 to December 2021 were collected retrospectively. These patients were randomly divided into a training dataset ( n=330) and a validation dataset ( n=141) at a ratio of 7∶3 by using the random function. All patients underwent two noncontrast CT examinations within 24 h and an increase in hematoma volume of >33% or an absolute increase in hematoma volume of >6 ml was considered hematoma enlargement. According to the presence or absence of hematoma enlargement, all patients were divided into hematoma enlargement group and hematoma non-enlargement group.Two-sample t test, Mann-Whitney U test or χ2 test were used for univariate analysis. The factors with statistically significant differences were included in multivariate logistic regression analysis, and independent influences related to hematoma enlargement were screened out to establish a clinical factor model. ITK-SNAP software was applied to manually label and segment the cerebral hemorrhage lesions on plain CT images to train and build a deep learning model based on ResNet50 architecture. A combination model for predicting hematoma expansion in cerebral hemorrhage was established by combining independent clinical influences with deep learning scores. The value of the clinical factor model, the deep learning model, and the combination model for predicting hematoma expansion in cerebral hemorrhage was evaluated using receiver operating characteristic (ROC) curves and decision curves in the training and validation datasets. Results:Among 471 cerebral hemorrhage patients, 136 cases were in the hematoma enlargement group and 335 cases were in the hematoma non-enlargement group. Regression analyses showed that male ( OR=1.790, 95% CI 1.136-2.819, P=0.012), time of occurrence ( OR=0.812, 95% CI 0.702-0.939, P=0.005), history of oral anticoagulants ( OR=2.157, 95% CI 1.100-4.229, P=0.025), admission Glasgow Coma Scale score ( OR=0.866, 95% CI 0.807-0.929, P<0.001) and red blood cell distribution width ( OR=1.045, 95% CI 1.010-1.081, P=0.011) were the independent factors for predicting hematoma expansion in cerebral hemorrhage. ROC curve analysis showed that in the training dataset, the area under the curve (AUC) of clinical factor model, deep learning model and combination model were 0.688 (95% CI 0.635-0.738), 0.695 (95% CI 0.642-0.744) and 0.747 (95% CI 0.697-0.793) respectively. The AUC of the combination model was better than that of the clinical model ( Z=0.54, P=0.011) and the deep learning model ( Z=2.44, P=0.015). In the validation dataset, the AUC of clinical factor model, deep learning model and combination model were 0.687 (95% CI 0.604-0.763), 0.683 (95% CI 0.599-0.759) and 0.736 (95% CI 0.655-0.806) respectively, with no statistical significance. Decision curves showed that the combination model had the highest net benefit rate and strong clinical practicability. Conclusions:Both the deep learning model and the clinical factor model established in this study have some predictive value for hematoma expansion in cerebral hemorrhage; the combination model established by the two together has the highest predictive value and can be applied to predict hematoma expansion.

Objective To analyze and compare the strength of titanium alloy crystalline porous scaffolds and porous scaffolds with a triply periodic minimal surface(TPMS)structure and explore the effect of porosity on the equivalent elastic modulus and permeability.Methods Crystalline porous scaffolds(cell 1-4)and TPMS porous scaffolds(P-,G-,D-,and FKS-type)with the same porosity were constructed,and the equivalent elastic modulus,equivalent yield strength,and permeability of the scaffolds were calculated using finite element simulation.Results The elastic modulus of eight scaffolds was in the range of 5.1-10.4 GPa,the yield strength was in the range of 69-110 MPa,and the permeability of 4 crystalline scaffolds was in the range of 0.015-0.030 mm2.Conclusions With an increase in porosity,the elastic modulus and yield strength of the scaffold gradually decreased,and the permeability gradually increased.The cell 2-type scaffold is suitable for repairing defects at load-bearing bone sites because of its high elastic modulus and yield strength.The cell 3-type scaffold with a uniform stress distribution and a longer linear elasticity phase may be suitable for designing porous tibial platforms for knee joint prostheses.

Endodontic diseases are a kind of chronic infectious oral disease.Common endodontic treatment concepts are based on the removal of inflamed or necrotic pulp tissue and the replacement by gutta-percha.However,it is very essential for endodontic treatment to debride the root canal system and prevent the root canal system from bacterial reinfection after root canal therapy(RCT).Recent research,encompassing bacterial etiology and advanced imaging techniques,contributes to our understanding of the root canal system's anatomy intricacies and the technique sensitivity of RCT.Success in RCT hinges on factors like patients,infection severity,root canal anatomy,and treatment techniques.Therefore,improving disease management is a key issue to combat endodontic diseases and cure periapical lesions.The clinical difficulty assessment system of RCT is established based on patient conditions,tooth conditions,root canal configuration,and root canal needing retreatment,and emphasizes pre-treatment risk assessment for optimal outcomes.The findings suggest that the presence of risk factors may correlate with the challenge of achieving the high standard required for RCT.These insights contribute not only to improve education but also aid practitioners in treatment planning and referral decision-making within the field of endodontics.

Objective To investigate the correlation between serum soluble fibrinogen like protein 2(sFGL2)and adipocyte fatty acid-binding protein(AFABP)with the severity and prognosis of patients with chronic heart failure.Methods A total of 102 confirmed chronic heart failure patients treated in Tangshan People's Hospital(the hospital)from June 2020 to June 2022 were regarded as the disease group.They were divided into grade Ⅱ group(28 cases),grade Ⅲ group(35 cases),and grade Ⅳ group(39 cases)based on their illness severity.They were separated into MACE group(44 cases)and non MACE group(58 cases)based on their prognosis.Additionally,102 healthy individuals who came to Tangshan People's Hospital for physical examination were regarded as the control group.The levels of serum sFGL2 and AFABP in each group were compared.Logistic regression was applied to analyze the influencing factors of poor prognosis in patients.Receiver operating characteristic(ROC)curve was applied to analyze the predictive value of serum sFGL2 and AFABP levels for poor prognosis in patients.Results Compared with the control group,the serum sFGL2 level in the diseased group was greatly reduced(P＜0.05),while the AFABP level was greatly in-creased(P＜0.05).The serum sFGL2 level in grade Ⅱ group,grade Ⅲ group,and grade Ⅳ group decreased sequentially(P＜0.05),while the AFABP level increased sequentially(P＜0.05).The heart rate and sFGL2 level in the MACE group were greatly lower than those in the non MACE group(P＜0.05),while the propor-tion of atrial fibrillation and AFABP level were greatly higher than those in the non MACE group(P＜0.05).Heart rate,atrial fibrillation,and AFABP were independent risk factors for MACE in patients(P＜0.05),while sFGL2 was an independent protective factor for MACE in patients(P＜0.05).The area under the curve(AUC)of serum sFGL2 and AFABP for predicting MACE in patients was 0.842 and 0.858,respectively,the AUC of the combination of the two was 0.943,and the combined prediction of the two was better than the in-dividual prediction(Zcombined prediction-sFGL2=2.898,P=0.004;Zcombinedprediction-AFABP=2.608,P=0.009).Conclusion Ser-um sFGL2 level is down regulated and AFABP level is up regulated in patients with chronic heart failure,which are influencing factors for the occurrence of MACE.The combination of the two has higher efficacy in predicting the prognosis of the patients.

Objective:To explore the efficacy of adjusting the dose of imatinib dose in the context of therapeutic drug monitoring (TDM) in patients with gastrointestinal stromal tumors (GISTs) who are receiving adjuvant therapy after complete resection of their tumors.Methods:This was a descriptive study. Inclusion criteria were (1) complete surgical resection with a pathological diagnosis of GIST, (2) postoperative adjuvant therapy with imatinib and dosage adjustment, (3) multiple TDM of imatinib, and (4) complete clinical, pathological, and follow-up data. The data of 70 patients with GISTs treated at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology between January 2015 and December 2023 were collected retrospectively. The study cohort comprised 15 (21.4%) men and 55 (78.6%) women of median age 60 years (range: 25–82). Of the eligible patients, 49 (70.0%) were at high-risk, 14 (20.0%) at intermediate-risk, six (8.6%) at low-risk, and one (1.4%) at very low risk. Patients were followed up by the gastrointestinal stromal tumor clinic every 2–3 months and their plasma concentrations of imatinib were checked. The dose was adjusted to 300 mg/d or 200 mg/d depending on whether they had had ≥ grade III adverse reactions, and whether the first plasma concentration of imatinib was ≥ 1,500 μg/L or between the expected range of 760 μg/L–1,100 μg/L. Studied indicators included adverse reactions, quality of life before and after dose adjustment, and overall survival and recurrence-free survival (RFS) after dose adjustment.Results:Before dose adjustment, all 70 patients received 400 mg of imatinib daily, with initial TDM values of 1,900 ± 568 μg/L, for a median duration of 8.3 months. After dose adjustment, 60 patients received 300 mg daily, with a TDM of 1,216 ± 350 μg/L, whereas 10 received 200 mg daily, with a TDM of 1,023 ± 269 μg/L. The median duration of treatment after dose adjustment was 23.4 months. Compared with those whose dosages were not adjusted, the incidence of bone marrow suppression was significantly lower (74.3% [52/70] vs. 51.4% [36/70], χ 2=9.202, P=0.010); as were the incidences of edema (95.7% [67/70] vs. 50.0% [35/70], χ 2=40.526, P<0.001); skin reactions (70.0% [49/70] vs. 32.9% [23/70), χ 2=22.495, P<0.001); and gastrointestinal reactions (38.6% [27/70] vs. 10.0% [7/70], χ 2=15.899, P<0.001) in those whose dosages were adjusted. The average total scores for physical health before and after dose adjustment were 76 ± 5 and 88 ± 4, respectively; whereas the mental health scores were 75 ± 6 and 89 ± 4, respectively. The median follow-up period was 36 months (range 6–126). During the first 3 years of follow-up, five high-risk patients with non-gastric GISTs developed recurrences. The 3-year overall survival rate was 100%, and the 3-year RFS rate was 92.8%, high-risk patients having a 3-year RFS rate of 89.8%. Conclusion:The adverse reactions and quality of life of GIST patients with severe adverse reactions to adjuvant imatinib therapy after complete resection can be mitigated by appropriately reducing the dosage of imatinib under the guidance of TDM.

There are several special types of tumors in the rectal and anal canal,such as neuroendocrine tumors(NETs),gastrointestinal stromal tumors(GIST),squamous cell anal carcinoma(SCAC),anorectal malignant melanoma(ARMM),and primary rectal lymphoma(PRL).They are rare and have different clinical characteristics from the rectal cancer,resulting in insufficient understanding of them by clinicians.This article reviews the diagnosis and treatment of special types of tumors in the rectal and anal region.

Objective To explore the changes in serum creatine kinase(CK)and myoglobin(Mb)levels in benign acute childhood myositis(BACM)and their clinical significance.Methods The clinical data of 78 children with BACM treated in our hospital from January 2011 to December 2023 were collected,and the dynamic changes and clinical performance of serum CK and Mb levels were re-trospectively analyzed.Results The CK levels of the 78 patients ranged from 432 U/L to 18 440 U/L,with the mean level being 2 178.8 U/L.The levels exceeded the upper reference limit(310 U/L)in all the patients.They were 2 and 10 times the upper reference limit in 72(92.31％)and 15(19.23％)patients,respectively,and were greater than 5 000 U/L in 5(6.41％)patients and greater than 10 000 U/L in 1 patient.The CK level usually peaked in the first 3 days of BACM onset before decreasing gradually.By the 7th day,CK levels in 73％of the cases decreased to the normal reference range,which was consistent with the change in clinical symptoms.Serum Mb samples were col-lected from 66 patients,and the levels ranged from 13.3 ng/mL to 2 603.8 ng/mL,with the mean level being 260.17 ng/mL.In 34 patients(51.52％),the Mb levels were higher than the upper reference limit(116.3 ng/mL).Among these patients,20(30.30％),7(10.61％),and 3(4.55％)patients had Mb levels 2,5,and 10 times higher than the upper reference limit,respectively.Serum Mb levels peaked in the first 3 days of BACM onset and then decreased quickly.Furthermore,in 84.38％of the total cases,serum Mb levels decreased to the normal reference range by the 5th day of onset.Conclusion Serum CK levels in children with BACM are significantly increased,consistent with the changes in clinical symptoms,and therefore,could be regarded as an important basis for BACM diagnosis.Furthermore,serum Mb levels increase to varying extents,indicating a great reference value in BACM diagnosis,and should be tested simultaneously with serum CK.Testing for serum CK and Mb is of great significance for understanding the clinical conditions and guiding the treatment of BACM.